Argenx is dedicated to advancing immunology through a collaborative approach that integrates the expertise of pioneering researchers with its own antibody engineering capabilities. The company has established an Immunology Innovation Program (IIP) that fosters partnerships with academic and scientific collaborators to accelerate the discovery of novel therapeutic antibodies. This co-creation model has led to a robust pipeline of differentiated product candidates aimed at addressing severe autoimmune diseases. Argenx emphasizes the importance of collaboration in driving innovation, believing that collective efforts can lead to significant breakthroughs in treatment options for patients.

The company’s proprietary SIMPLE Antibody™ platform is designed to source unique antibody variable regions from the immune systems of outbred llamas, enhancing the potential for novel therapeutic targets. Additionally, Argenx employs advanced Fc engineering technologies, including NHANCE®, ABDEG™, and POTELLIGENT®, to optimize the therapeutic index of its antibodies. These technologies enable the development of differentiated medicines that can effectively modulate immune responses, thereby addressing complex disease pathways associated with conditions such as myasthenia gravis and other severe autoimmune disorders. Through these innovative strategies, Argenx aims to transform scientific discoveries into viable treatment options for patients in need.

United States

Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan.

Eye Diseases

Genetic Diseases

Hematologic Diseases

Immune System Diseases

Musculoskeletal Diseases

Nervous System Diseases

Pathological Conditions

Skin Diseases

Argenx

Chronic inflammatory disorder

<p class="font_8">VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).</p>

VYVGART Hytrulo (Efgartigimod)

Autoimmune disease

Myasthenia gravis

<p class="font_8">Efgartigimod is an antibody fragment designed to reduce pathogenic immunoglobulin G (IgG) antibodies by binding to the neonatal Fc receptor and blocking the IgG recycling process. Efgartigimod is being investigated in several autoimmune diseases known to be mediated by disease-causing IgG antibodies, including neuromuscular disorders, blood disorders, and skin blistering diseases, in both an intravenous and subcutaneous (SC) formulation. SC efgartigimod is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology.</p>

VYVGART Hytrulo (SC Efgartigimod)

VYVGART Hytrulo pre-filled syringe (PFS)

Multifocal motorneuropathy

Neuromuscular disease

Neuropathy

Empasiprubart

Primary immune thrombocytopenia

Efgartigimod  

Sjögren-Larsson Syndrome

Polyneuropathy

Post-COVID Postural Orthostatic Tachycardia Syndrome

Efgartigimod 

Delayed graft function

Empasiprubart 

Dermatomyositis

Anti-synthetase syndrome

Idiopathic inflammatory myopathy / myositis

Immune-mediated necrotizing myopathy

Efgartigimod

Amyotrophic lateral sclerosis

ARGX -119

Congenital myasthenic syndrome

Inflammatory disease

ARGX-109

ARGX-213

ARGX-121

Mucosal Pemphigus Vulgaris

Boston, Massachusetts, United States of America

Massachusetts

Antibodies

Biologics

Therapeutic

Argenx

Company Details